| Primary |
|
|
| Secondary |
| Hypertension |
23.8% |
| Cardiac Failure |
14.3% |
| Coronary Artery Disease |
11.9% |
| Renal Osteodystrophy |
9.5% |
| Cardiac Pacemaker Insertion |
7.1% |
| Oedema Peripheral |
7.1% |
| Chronic Obstructive Pulmonary Disease |
4.8% |
| Hypereosinophilic Syndrome |
4.8% |
| Type 2 Diabetes Mellitus |
4.8% |
| Aortic Valve Stenosis |
2.4% |
| Atrial Fibrillation |
2.4% |
| Dyslipidaemia |
2.4% |
| Hyperuricaemia |
2.4% |
| Prophylaxis |
2.4% |
|
| Hepatitis |
22.2% |
| Haemorrhage |
11.1% |
| Hyponatraemia |
11.1% |
| Hypovolaemic Shock |
11.1% |
| Metabolic Alkalosis |
11.1% |
| Renal Failure Acute |
11.1% |
| Toxic Epidermal Necrolysis |
11.1% |
| Urethral Haemorrhage |
11.1% |
|
| Concomitant |
| Drug Use For Unknown Indication |
17.0% |
| Product Used For Unknown Indication |
14.0% |
| Hypertension |
11.7% |
| Pain |
8.7% |
| Acne |
8.5% |
| Oedema |
4.2% |
| Cachexia |
3.9% |
| Squamous Cell Carcinoma |
3.9% |
| Eczema |
3.6% |
| Diabetes Mellitus |
2.9% |
| Pulmonary Arterial Hypertension |
2.9% |
| Adverse Event |
2.5% |
| Breast Cancer |
2.3% |
| Anxiety |
2.2% |
| Cardiac Failure |
2.2% |
| Hyperparathyroidism Secondary |
2.2% |
| Prophylaxis |
2.1% |
| Nausea |
1.8% |
| Neoplasm Malignant |
1.8% |
| Chronic Obstructive Pulmonary Disease |
1.6% |
|
| Uterine Prolapse |
19.0% |
| Vomiting |
11.6% |
| Rectal Haemorrhage |
9.1% |
| Renal Failure Acute |
5.8% |
| Weight Increased |
5.0% |
| Xerosis |
5.0% |
| Subdural Haematoma |
4.1% |
| Urinary Tract Infection |
4.1% |
| Weight Decreased |
4.1% |
| Dehydration |
3.3% |
| Infection |
3.3% |
| Keratoconjunctivitis Sicca |
3.3% |
| Prothrombin Time Prolonged |
3.3% |
| Pyrexia |
3.3% |
| Tendonitis |
3.3% |
| Cerebrovascular Accident |
2.5% |
| Insomnia |
2.5% |
| Nausea |
2.5% |
| Pleural Effusion |
2.5% |
| Respiratory Failure |
2.5% |
|
| Interacting |
| Cardiac Failure |
28.6% |
| Asthma |
21.4% |
| Renal Osteodystrophy |
14.3% |
| Endocarditis Fibroplastica |
7.1% |
| Hypereosinophilic Syndrome |
7.1% |
| Product Used For Unknown Indication |
7.1% |
| Prophylaxis Against Gastrointestinal Ulcer |
7.1% |
| Thrombosis Prophylaxis |
7.1% |
|
| Blood Sodium Decreased |
50.0% |
| Metabolic Alkalosis |
50.0% |
|
